$SIBN

DUNN JEFFREY W sold $378K of SIBN

DUNN JEFFREY W sold 20,000 shares of SI-BONE, Inc. (SIBN) at $18.91 ($0.38M total) across 2 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DUNN JEFFREY W
Published Sep 3, 2026, 11:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SIBN
Bearish
medium confidence
Mentioned
$SIBN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNBearishLow
01

Why it matters

The disclosed sale adds a data point for investors monitoring insider sentiment.

02

Market read

A modest insider sale; limited immediate market impact but useful for sentiment tracking.

03

What to watch

The director retains 16,057 shares, indicating continued confidence; overall insider ownership remains sizable.

Relevance 3/10Novelty 5/10Timing: filed 2026-09-03, effective immediately

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan allows pre‑scheduled sales.

Company-level read

Ticker impact

$SIBNBearishMedium confidence
Context

Director Jeffrey Dunn sold 20,000 shares for $378,160 via a 10b5-1 plan on 2026-09-01.

Expected impact

Possible modest downside of 1‑2% in the near term.

Evidence & confidence

Sale size is modest relative to market cap, but insider disposition is a bearish indicator.

Market effects

Minimal; limited impact on the broader orthopedic device sector.

None; the filing is company‑specific.

Low; no broader market effect.

Counterpoint

The sale could be routine portfolio rebalancing under a pre‑arranged plan, not a negative signal.

Key entities

  • Jeffrey Dunn

    Director of SI‑BONE, Inc. who executed the sale.

  • SI‑BONE, Inc.

    Medical device company specializing in orthopedic implants.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIBNHigh

SI-BONE, Inc. (SIBN): Results of Operations and Financial Condition

SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to t